New innovative, rapid, tear-based, POC diagnostic test platform is designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders

 

At this year’s Expo of the American Academy of Ophthalmology AAO 2022 – booth # 1251, Verséa Ophthalmics is launching their comprehensive Product Portfolio and demonstrating a novel, point-of-care diagnostic test platform.

The platform, which allows rapid, accurate and non-invasive differential diagnosis and treatment assessment, includes:

– a portable multifunctional digital reader
– two specific tear-based quantitative biomarker tests (IgE and Lactoferrin) associated with Dry Eye Disease and non-specific allergic conjunctivitis.

These first FDA-cleared diagnostic tear-based tests are reimbursable under CPT codes authorized by the AMA and the ACP. They require the collection of 0.5 microliters in tears and provide quantitative results in under 10 minutes, an industry-leading return time.

The portfolio also includes complementary Regenerative Therapeutics that will enhance clinical management and treatment decisions that ultimately lead to better patient care.

We hope to see you there!

Dr. Rob Sambursky
President of Verséa™ Ophthalmics, LLC

………….

About Verséa™ Ophthalmics
Verséa™ Ophthalmics, LLC, a business division of Verséa Holdings, Inc. (“Verséa”), is one of the fastest growing U.S. healthcare companies on a mission to revolutionize eye care. It is specialized in the sale and distribution of innovative solutions for the diagnosis, treatment, and management of ocular surface diseases. To learn more, visit Verséa™ Ophthalmics webpage

The new diagnostic platform is a result of an exclusive global commercial partnership with AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech” or “AXIM”), an international healthcare solutions company targeting ocular surface diseases.